Omezolan 40 (Omeprazole)

Omeprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions:

• Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis.
• Peptic ulcer disease: supports ulcer healing and reduces recurrence risk.
• Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with the condition.
• Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.
• Erosive gastritis: aids mucosal healing by maintaining a higher gastric pH.

• Omeprazole irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly reduces both basal and stimulated gastric acid secretion, leading to an increase in gastric pH and facilitating mucosal healing.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually self‑limiting.
• Nausea or vomiting: transient gastrointestinal upset.
• Abdominal pain or discomfort: mild cramping.
• Flatulence: excess gas production.
• Constipation: occasional bowel habit change.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rash, swelling, airway compromise.
• Clostridioides difficile‑associated colitis: watery diarrhea, abdominal pain.
• Acute interstitial nephritis: renal impairment, hematuria.
• Osteoporotic fractures: increased risk with long‑term use.
• Hypomagnesemia: low serum magnesium, muscle cramps, arrhythmia.
• Vitamin B12 deficiency: anemia, neuropathy with prolonged therapy.

When prescribing Omeprazole, consider the following precautions:

• Assess renal and hepatic function: dose adjustment may be required in severe impairment.
• Review long‑term use: evaluate need after 8‑12 weeks to avoid potential complications.
• Monitor for infection risk: prolonged acid suppression may increase susceptibility to gastrointestinal infections.
• Counsel on drug interactions: many agents alter omeprazole metabolism or efficacy.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk.
• Atazanavir or other protease inhibitors: decreased absorption, loss of antiviral efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, monitor coagulation parameters.
• Phenytoin: reduced serum levels, monitor seizure control.
• Methotrexate (high dose): increased exposure, watch for toxicity.
• Digoxin: modest rise in serum concentration, assess for signs of toxicity.